WO2013130577A3 - Compositions et méthodes pour le traitement de la migraine - Google Patents

Compositions et méthodes pour le traitement de la migraine Download PDF

Info

Publication number
WO2013130577A3
WO2013130577A3 PCT/US2013/027983 US2013027983W WO2013130577A3 WO 2013130577 A3 WO2013130577 A3 WO 2013130577A3 US 2013027983 W US2013027983 W US 2013027983W WO 2013130577 A3 WO2013130577 A3 WO 2013130577A3
Authority
WO
WIPO (PCT)
Prior art keywords
migraine
treatment
alpha
compositions
methods
Prior art date
Application number
PCT/US2013/027983
Other languages
English (en)
Other versions
WO2013130577A2 (fr
Inventor
Gerald Horn
Original Assignee
Eye Therapies, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/406,321 external-priority patent/US20120156244A1/en
Application filed by Eye Therapies, Llc filed Critical Eye Therapies, Llc
Priority to EP13754567.9A priority Critical patent/EP2819674A2/fr
Priority to CA2865593A priority patent/CA2865593A1/fr
Priority to JP2014558959A priority patent/JP2015517980A/ja
Publication of WO2013130577A2 publication Critical patent/WO2013130577A2/fr
Publication of WO2013130577A3 publication Critical patent/WO2013130577A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques pour le traitement d'une congestion nasale ou d'une migraine, les compositions pharmaceutiques comprenant de faibles concentrations d'une sous classe super-sélective d'agonistes sélectifs du récepteur α-2 adrénergique.
PCT/US2013/027983 2012-02-27 2013-02-27 Compositions et méthodes pour le traitement de la migraine WO2013130577A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP13754567.9A EP2819674A2 (fr) 2012-02-27 2013-02-27 Compositions et méthodes pour le traitement de la migraine
CA2865593A CA2865593A1 (fr) 2012-02-27 2013-02-27 Compositions et methodes pour le traitement de la migraine
JP2014558959A JP2015517980A (ja) 2012-02-27 2013-02-27 片頭痛の治療のための組成物および方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/406,321 US20120156244A1 (en) 2008-08-01 2012-02-27 Nasal Compositions and Uses Thereof
US13/406,321 2012-02-27

Publications (2)

Publication Number Publication Date
WO2013130577A2 WO2013130577A2 (fr) 2013-09-06
WO2013130577A3 true WO2013130577A3 (fr) 2015-03-12

Family

ID=49083441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/027983 WO2013130577A2 (fr) 2012-02-27 2013-02-27 Compositions et méthodes pour le traitement de la migraine

Country Status (4)

Country Link
EP (1) EP2819674A2 (fr)
JP (1) JP2015517980A (fr)
CA (1) CA2865593A1 (fr)
WO (1) WO2013130577A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020259440A1 (fr) * 2019-06-28 2020-12-30 四川普锐特药业有限公司 Pulvérisation nasale de dexmédétomidine, son procédé de préparation et son utilisation

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2835398T3 (es) 2013-02-01 2021-06-22 Ocuphire Pharma Inc Métodos y composiciones para la administración oftálmica diaria de fentolamina para mejorar el rendimiento visual
EP2950648B1 (fr) 2013-02-01 2019-09-18 Ocuphire Pharma, Inc. Solutions ophtalmiques aqueuses de phentolamine et utilisations médicales associées
EP3562486B1 (fr) 2016-12-31 2024-03-13 Bioxcel Therapeutics, Inc. Utilisation de dexmédétomidine sublinguale permettant le traitement de l'agitation
AU2018380300B2 (en) * 2017-12-08 2022-06-16 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
BR112020026672A2 (pt) 2018-06-27 2021-03-30 Bioxcel Therapeutics, Inc. Formulações de filme contendo dexmedetomidina e métodos para produzi-las
WO2020087021A1 (fr) 2018-10-26 2020-04-30 Ocuphire Pharma, Inc. Méthodes et compositions pour le traitement de la presbytie, de la mydriase et d'autres troubles oculaires
CA3145388A1 (fr) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Regimes de traitement non sedatifs a base de dexmedetomidine
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486190B1 (en) * 1997-11-24 2002-11-26 The Procter & Gamble Company 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
US20020192288A1 (en) * 2000-06-26 2002-12-19 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US20090220611A1 (en) * 2005-09-30 2009-09-03 Frederic Dargelas Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same
US20110021588A1 (en) * 2009-05-15 2011-01-27 Recro Pharma, Inc. Sublingual dexmeditomidine compositions and methods of use thereof
US20110257188A1 (en) * 2008-08-01 2011-10-20 Gerald Horn Compositions and methods for the treatment of nasal conditions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486190B1 (en) * 1997-11-24 2002-11-26 The Procter & Gamble Company 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
US20020192288A1 (en) * 2000-06-26 2002-12-19 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US20090220611A1 (en) * 2005-09-30 2009-09-03 Frederic Dargelas Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same
US20110257188A1 (en) * 2008-08-01 2011-10-20 Gerald Horn Compositions and methods for the treatment of nasal conditions
US20110021588A1 (en) * 2009-05-15 2011-01-27 Recro Pharma, Inc. Sublingual dexmeditomidine compositions and methods of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020259440A1 (fr) * 2019-06-28 2020-12-30 四川普锐特药业有限公司 Pulvérisation nasale de dexmédétomidine, son procédé de préparation et son utilisation

Also Published As

Publication number Publication date
JP2015517980A (ja) 2015-06-25
EP2819674A2 (fr) 2015-01-07
CA2865593A1 (fr) 2013-09-06
WO2013130577A2 (fr) 2013-09-06

Similar Documents

Publication Publication Date Title
WO2013130577A3 (fr) Compositions et méthodes pour le traitement de la migraine
WO2010037059A3 (fr) Antagonistes hétéroaryliques des récepteurs de prostaglandine d<sb>2</sb>
WO2008021851A3 (fr) Nouveaux composés comme antagonistes ou agonistes inverses pour les récepteurs d'opioïdes
WO2010039977A3 (fr) Antagonistes d'hétéroaryle des récepteurs de la prostaglandine d2
WO2009108720A3 (fr) Antagonistes des récepteurs d2 de la prostaglandine
WO2010077883A3 (fr) Antagonistes des récepteurs d'acide lysophosphatidique
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2010057118A3 (fr) Antagonistes hétérocycliques des récepteurs de la prostaglandine d2
WO2011103202A3 (fr) Modulateurs du récepteur des androgènes et leurs utilisations
WO2010003127A3 (fr) Antagonistes des récepteurs de la prostaglandine d<sb>2</sb>
WO2012037411A3 (fr) Modulateurs des récepteurs des oestrogènes et leurs utilisations
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
WO2009102893A3 (fr) Composés diaryliques cycliques en tant qu'antagonistes de récepteurs de prostaglandine d<sb>2</sb>
WO2010042652A3 (fr) Antagonistes hétéroalkyl biphényle des récepteurs de la prostaglandine d2
WO2010068775A3 (fr) Antagonistes d'alcyne de récepteurs d'acide lysophosphatidique
WO2010141768A3 (fr) Antagonistes polycycliques de récepteurs d'acide lysophosphatidique
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
WO2011159769A3 (fr) Modulateurs de récepteur d'œstrogène d'indane et utilisations de ceux-ci
WO2008021849A3 (fr) Nouveaux composés comme antagonistes ou agonistes inverses à des récepteurs d'opioïdes
WO2009115547A8 (fr) 1,2,4-triazoles trisubstitués comme modulateurs des récepteurs nicotiniques à l'acétylcholine
EP3632444A3 (fr) Antagonistes lfa-1 topiques pour une utilisation dans le traitement localisé de troubles immunitaires associés
WO2010014172A3 (fr) Particule de vectorisation
WO2008121348A3 (fr) Antagonistes de récepteurs opioïdes périphériques, et leurs utilisations
WO2010085820A3 (fr) Composés tricycliques en tant qu'antagonistes des récepteurs d2 de la prostaglandine
WO2014066799A3 (fr) Modulateurs du récepteur des androgènes androgéno-résistant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13754567

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2865593

Country of ref document: CA

Ref document number: 2014558959

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013754567

Country of ref document: EP